Every Form 4 that GlucoTrack, Inc. (GCTK) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GCTK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GCTK filings page.
Insider transactions by Director Andrew K. Balo increased his reported beneficial stake in Glucotrack, Inc. (GCTK) through several non‑derivative share grants and a stock option award. The filing records three non‑derivative stock acquisitions on 03/25/2025, 07/11/2025 and 10/03/2025 that cumulatively bring his reported direct beneficial ownership to 4,692 common shares. The filing also shows a stock option granted on 10/03/2025 to buy 4,055 shares at an exercise price of $7.4, exercisable on 10/03/2025 and expiring on 10/03/2035. The report states option vesting starts each July 1 and vests monthly over 12 months, subject to continued service. All reported figures reflect three disclosed reverse stock splits completed in 2024, 02/25/2025, and 06/13/2025.
Glucotrack, Inc. director Luis Malave reported multiple stock option and common stock acquisition transactions across 2025 that increase his direct ownership. The filing shows three non‑derivative common stock acquisitions: 35 shares on 03/25/2025, 1,200 shares on 07/11/2025, and 463 shares on 10/03/2025, bringing his total direct common shares to 4,058. The filing also records a derivative transaction on 10/03/2025 for a stock option exercisable at $7.4 covering 4,055 underlying shares that expire on 10/03/2035, leaving 4,055 options held directly.
The reported grants vest monthly over 12 months starting each July 1, subject to continued service. The filing notes multiple reverse stock splits in 2024 and 2025 and states all figures reflect those splits. The report was signed by an attorney‑in‑fact on 10/07/2025.
Glucotrack, Inc. (GCTK) director Erin Catherine Carter reported multiple equity awards and exercises that increased her direct common stock holdings and option position. On 03/25/2025 she was recorded as acquiring 32 shares, followed by 1,000 shares on 07/11/2025 and 386 shares on 10/03/2025, bringing total directly held common stock to 2,148 shares after those transactions. The filing also shows an option grant exercisable beginning 10/03/2025 for 4,055 shares with an exercise price of $7.4 and an expiration in 10/03/2035. The Form 4 notes standard vesting that begins on July 1 of the applicable year and vests monthly over 12 months, and it discloses that reported share figures reflect a series of reverse stock splits implemented in 2024, 02/25/2025, and 06/13/2025.
Glucotrack, Inc. (GCTK) reported an insider transaction on Form 4. The company’s Chief Executive Officer and director received 42 shares of common stock on 03/25/2025, issued upon achievement of a milestone under an October 7, 2022 Intellectual Property Purchase Agreement. The transaction is coded J (other).
Following this issuance, the reporting person beneficially owns 339 shares, held directly. The company notes that all figures reflect reverse stock splits implemented on 05/17/2024, 02/25/2025, and 06/13/2025.